S-1/A: OSR Holdings Secures $83.9M in New Capital Amidst Widening Losses and Prior Insolvency

OSR Holdings, a global healthcare holding company, has filed an amended registration statement to allow for the resale of up to 15.41 million shares by White Lion Capital, potentially securing up to $83.9 million in new capital through equity line, warrant, and convertible note agreements, while reporting a significant net loss for Q1 2025.

Summary

• OSR Holdings operates as a global healthcare holding company with a 'hub-and-spoke' business model, focusing on drug development in oncology, immunology, and degenerative diseases, and medical device distribution.
• The company recently completed a business combination with OSR Holdings, Ltd. (Korea) on February 14, 2025, and subsequently changed its name from Bellevue Life Sciences Acquisition Corp.
• This filing registers for resale up to 15,410,000 shares of common stock by White Lion Capital LLC, which includes up to 9,500,000 shares from an equity line of credit (ELOC) agreement, 800,000 commitment shares, 4,000,000 shares from a Common Stock Purchase Warrant, and 1,110,000 shares convertible from Senior Secured Convertible Promissory Notes.
• The company expects to receive up to $83.9 million in aggregate gross proceeds from White Lion through these issuance agreements, which will be used to fund clinical trials, preclinical product candidates, potential acquisitions, and general corporate purposes.
• For the three months ended March 31, 2025, OSR Holdings reported a net loss of $11,392,814, a substantial increase from the $3,355,366 net loss in Q1 2024.
• Net sales decreased by 16% to $761,272 in Q1 2025 from $910,225 in Q1 2024, primarily due to the termination of a key customer relationship (Penumbra) for its RMC subsidiary.
• Operating loss slightly improved to $(2,917,826) in Q1 2025 from $(3,302,528) in Q1 2024, mainly due to lower amortization expenses.
• Other expenses increased significantly by $8.4 million, attributed to one-time merger-related expenses associated with the business combination.
• The company had $1,595,697 in cash and cash equivalents as of March 31, 2025, and an accumulated deficit of $30.6 million.
• A previously agreed $20 million Private Investment in Public Equity (PIPE) transaction was cancelled due to macroeconomic factors in Korea, leading to the company being insolvent at the business combination closing date and necessitating the current alternative financing arrangements.

Sentiment

Score: 3

Explanation: The company reported a significantly widened net loss and decreased revenue, primarily due to one-time merger expenses and the loss of a key customer. The cancellation of a $20 million PIPE transaction led to insolvency at the business combination closing, highlighting severe liquidity issues. While new financing agreements (ELOC, warrants, convertible notes) are in place, offering up to $83.9 million in potential capital, these involve substantial dilution risk (43% of outstanding shares) and are subject to market conditions. The company's long-term prospects depend heavily on successful clinical trials and commercialization, which are inherently risky and costly. The current financial state is precarious, despite the secured financing lifeline.

Positives

• Secured new financing agreements (ELOC, Warrant, Convertible Notes) with White Lion Capital, potentially providing up to $83.9 million in gross proceeds to fund operations and development.
• Successfully completed the business combination with OSR Holdings, Ltd. on February 14, 2025, establishing the company as a global healthcare holding entity.
• Vaximm's flagship asset, VXM01, is a late clinical-stage immuno-oncology candidate for glioblastoma, which has received Orphan Drug Designation from both the U.S. FDA and European EMA, potentially offering market exclusivity.
• Darnatein's DRT-102 showed potential efficacy in a small exploratory clinical trial for spinal fusion with no serious adverse events.
• Darnatein's DRT-101 demonstrated cartilage regeneration and joint healing in preclinical animal trials with no serious adverse events.
• RMC has established strong relationships with leading university and general hospitals in Korea and a nationwide sales network, enhancing its competitiveness in the medical device distribution market.
• The company's interdisciplinary leadership team combines deep scientific, legal, and financial expertise to advance its diverse portfolio.
• The company has maintained its listing on the Nasdaq Capital Market following compliance with listing standards after its business combination.

Negatives

• Reported a significant net loss of $11,392,814 for the three months ended March 31, 2025, a 240% increase compared to the $3,355,366 net loss in the same period of 2024.
• Net sales decreased by 16% to $761,272 in Q1 2025, primarily due to the termination of a key distribution agreement with Penumbra Inc. for the RMC subsidiary.
• Gross margin percentage decreased from 26.3% to 22.2% due to the depreciation of the Korean Won, which increased the cost of imported goods for RMC.
• Other expenses increased significantly by $8.4 million due to one-time merger-related expenses associated with the business combination.
• The previously agreed $20 million PIPE transaction was cancelled by the investor due to macroeconomic factors, resulting in the company being insolvent at the business combination closing date and lacking sufficient cash.
• The company has a limited operating history and its drug development programs are in early stages, making future success uncertain.
• The company is expected to incur significant operating losses for the foreseeable future and may never achieve or maintain profitability.
• The potential issuance of up to 15,410,000 shares (approximately 43% of current outstanding shares) under the new financing agreements, coupled with discounted purchase prices for White Lion Capital, poses a substantial dilution risk for existing shareholders.
• The company currently lacks an internal marketing and sales organization for pharmaceutical products, relying on third parties, which will require significant future investment to develop.
• The management team has limited experience managing and operating a U.S. public company.

Risks

• The company requires substantial additional funding and its inability to raise capital when needed could force delays, reductions, or cessation of product development programs, future acquisitions, and commercialization efforts.
• The company was insolvent as of the business combination closing date due to the cancelled $20 million PIPE transaction, leading to a lack of sufficient cash and potential claims from creditors, which could result in bankruptcy proceedings and render stock and warrants worthless.
• The price of the company's Common Stock and warrants may be volatile, and investors will suffer immediate and potentially substantial dilution from the issuance of up to 15,410,000 shares (approximately 43% of total outstanding shares) under the new financing agreements.
• White Lion Capital will pay less than the then-prevailing market price for common stock, and its subsequent resales could cause the stock price to decline.
• The company is a 'controlled company' under Nasdaq Listing Rules, allowing it to rely on exemptions from certain corporate governance requirements, which may reduce protections for stockholders.
• An active, liquid trading market for the company's Common Stock and warrants may not develop or persist, limiting investors' ability to sell securities.
• The company's limited operating history and the early stage of its development programs make it difficult to evaluate its prospects and likelihood of success, with preclinical programs potentially never advancing to clinical trials.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and failure to obtain regulatory approval would materially harm the business.
• The company will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability.
• There is a risk of not being successful in efforts to acquire, in-license, or discover and develop new product candidates.
• Reliance on third-party providers for discovery, clinical development, and manufacturing functions carries significant risks.
• The company faces substantial competition from other pharmaceutical, biotechnology, and medical device companies, which may develop more effective or less costly products, or obtain intellectual property rights more rapidly.
• Inability to obtain and maintain patent and other intellectual property protection for technology and product candidates, or insufficient scope of protection, could hinder effective competition.
• Failure to comply with Nasdaq continued listing standards could result in delisting, reduced liquidity, and limited access to capital.
• Provisions in the corporate charter documents and Delaware law could make an acquisition of the company more difficult and may prevent attempts by stockholders to replace or remove current management.
• Exclusive forum provisions in the certificate of incorporation and bylaws may limit stockholders' ability to bring claims in preferred judicial forums, potentially increasing litigation costs.
• Management has broad discretion over the use of proceeds from the Issuance Agreements, which may not align with investor expectations or yield significant returns.
• The company does not anticipate paying any cash dividends in the foreseeable future, requiring stockholders to rely solely on capital appreciation for returns.
• The company's status as an emerging growth company and smaller reporting company allows for reduced disclosure obligations, which may make its securities less attractive to some investors and comparisons with other public companies difficult.
• The company may redeem unexpired public warrants after they become exercisable and prior to their exercise at a time disadvantageous to holders, potentially making them worthless.
• A civil action has been filed against the company by Benjamin Securities, Inc. seeking $500,000 in brokerage fees and costs.

Future Outlook

OSR Holdings anticipates a decrease in revenue for 2025 and potentially longer, until its RMC subsidiary can replace sales lost from the terminated Penumbra agreement. The company expects to significantly increase R&D expenses, projecting $2.5 million to $3.0 million per quarter starting mid-2025, potentially rising to $5.0 million to $6.0 million per quarter, to advance its product candidates. Vaximm's first oral cancer vaccine candidate beyond VXM01 is expected to enter clinical trials within 3-5 years, with potential regulatory approval in 7-9 years. Darnatein plans to file an IND for DRT-101 by 2025, aiming for FDA approval by 2032, and will seek cash flow through licensing deals. The net proceeds from the new financing agreements are intended to fund these clinical trials, preclinical development, potential acquisitions, and general corporate purposes. The company will continue to rely on third parties for manufacturing and commercialization support, with a long-term goal of building an in-house marketing and sales organization.

Management Comments

• "Our mission is to leverage our existing and expanding network of academic and industry leaders and investors, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research."
• "We expect to attract industry partners either as co-investors or through technology licensing deals and may raise capital directly from private, strategic or public investors."
• "We seek to chart a potentially more efficient and optimal route by pairing what we believe are the right team and pharmaceutical or medical device technologies that have the potential to treat diseases and improve healthcare outcomes with the necessary financial and other resources."
• "Our overarching goal is to enhance value creation for our subsidiaries by continuously assessing optimal development options and exploring partnership and fundraising opportunities."
• "We believe our strong foundational scientific conviction, entrepreneurial acumen and opportunistic approach positions us as a differentiated global company advancing pharmaceutical and medical device technologies in an efficient, cost-effective and meaningful manner."
• "OSR Holdings expects revenue to decrease in 2025 and possibly longer until RMC can replace the sales of Penumbras products by increasing other sales or securing additional products from other manufacturers."
• "The slight improvement [in operating loss] was primarily driven by a reduction in SG&A expenses, largely attributable to lower amortization expenses following a change in the useful lives of certain intangible assets. This benefit was partially offset by an increase in personnel-related expenses."
• "The Company intends to manage all valid arrears in its debts and liability accounts as soon as monies become available from anticipated near-term financing arrangements."

Industry Context

OSR Holdings operates as a global healthcare holding company, employing a 'hub-and-spoke' business model to foster growth in its subsidiaries across diverse therapeutic areas, including oral T-cell immunotherapies for cancer, design-augmented biologics for degenerative diseases, and neurovascular medical device distribution. This approach aims to diversify risk and leverage innovative research. The company's strategy is set within an industry where large global businesses frequently acquire healthcare companies, suggesting a potential exit strategy through subsidiary sales. In the medical device sector, its RMC subsidiary targets the South Korean market, which is experiencing increasing demand for medical equipment due to a rapidly aging population and a rise in cerebrovascular diseases. The company seeks to overcome common industry limitations such as high production costs and off-target effects in targeted immunotherapies through its innovative platform.

Comparison to Industry Standards

• Vaximm's VXM01 for glioblastoma competes with established players and their drug candidates, including AbbVie's Depatuxizumab mafodotin (ABT-414, Phase 2/3), AstraZeneca's Durvalumab (MEDI4736, Phase 2), Bayer's Regorafenib (Phase 2), DNAtrix's Tasadenoturev (DNX-2401, Phase 2), VBL Therapeutics' Ofranergene obadenovec (VB-111, Phase 3), Aivita Biomedical's AV-GBM-1 (Phase 2), and Kintara Therapeutics' VAL-083 (Phase 2/3).
• Darnatein's DRT-101 for osteoarthritis competes with Disease-Modifying Osteoarthritis Drugs (DMOADs) under development by companies such as Kolon TissueGene (Invossa, Phase 3), Biosplice Therapeutics (Lorecivivint, Phase 3), and Merck KGaA/EMD serono (Sprifermin, Phase 2).
• Darnatein's DRT-102 for spinal fusion competes with commercialized orthopedic solutions like Medtronic's Infuse Bone Graft, NuVasive's Osteocel Plus, Stryker's Bio4, Cerapedics' i-Factor, and Novabone's Novabone IRM.
• RMC's neurovascular device distribution business in South Korea competes with international brands such as Medtronic (React catheter, Axium prime coil system), Stryker (AXS infinity catheter, AXS catalyst 7 distal access catheter, Synchro wire, GDC coil system), Microvention (Traxcess wire, Microplex coil system), Cerenovous (Envoy guide catheter), and Boston Scientific (Guider soft tip guide catheter).

Management Changes

Corporate Governance

Legal Proceedings

• In March 2025, Company Management became aware of a civil action filed against the Company by Benjamin Securities, Inc. in Supreme Court, New York County, seeking $500,000.00 in brokerage fees and costs. The Company intends to manage all valid arrears in its debts and liability accounts as soon as monies become available from anticipated near-term financing arrangements.
• There are no other pending material litigation cases arising in the ordinary course of business as of March 31, 2025, and December 31, 2024.

Related Party Transactions

• **Bellevue Global Life Sciences Investors, LLC (Sponsor)**: Issued 1,437,500 founder shares for $25,000 (adjusted to 1,725,000 shares after stock split); purchased 430,000 Private Placement Units for $4,300,000; loaned $1,200,000 for IPO expenses (repaid); pays $7,500/month for office space/support; may loan up to $1,000,000 for transaction costs (convertible into units); issued unsecured promissory notes totaling $1,690,000 (April-July 2024), with maturity dates extended to September 30, 2025.
• **BCM Europe AG (Major Shareholder of Parent)**: Sponsor entered into promissory notes with BCM Europe for $3,400,000 (March 2022) and $2,000,000 (February 2023), with maturity dates extended; acquired Vaximm from BCM Europe AG in December 2022; held $860,000 in short-term borrowing from BCM Europe AG as of March 31, 2025.
• **Bellevue Capital Management LLC (Ultimate Parent Entity)**: Kuk Hyoun Hwang is founder and managing partner; subject to lock-up agreements for shares received in the Share Exchange.
• **Kuk Hyoun Hwang (CEO & Director)**: Controls approximately 67.8% of voting power; founder and managing partner of BCM; Chairman of Vaximm AG; former CEO/Chairman of OSR; CEO of BCME; has interests in the business combination that may differ from other stockholders.
• **Jun Chul Whang (Chief Legal Officer & Secretary, Director)**: Advisor to BCM; minority owner of BCM; issued unsecured promissory notes for $75,000 (February 2024) and $40,000 (October 2024), both non-interest bearing and with extended maturity dates.
• **Josh Pan (Individual member of Bellevue Capital Management, LLC)**: Issued an unsecured promissory note for $60,000 (March 2024), non-interest bearing, with an extended maturity date.
• **Duksung Co., LTD.**: Issued an unsecured promissory note for $800,000 (October 2024) at 5% interest (7% for prepayment), convertible into common stock at $8.10/share upon a Qualified PIPE Financing (which did not occur).
• **Toonon Partners Co., Ltd.**: Previously entered into a Subscription Agreement for a $20,000,000 PIPE Investment (October 2024), which was subsequently cancelled due to macroeconomic factors.
• **White Lion Capital LLC dba White Lion GBM Innovation Fund (Selling Stockholder)**: Entered into ELOC Agreement, Warrant Agreement, and Note Purchase Agreement (Issuance Agreements) in February/May 2025, through which the company expects to receive up to $83.9 million in gross proceeds; White Lion will purchase shares at discounted prices and is subject to beneficial ownership limitations.
• **Joint Center for Biosciences**: Darnatein maintains and uses manufacturing facilities owned by this affiliate and company shareholder for R&D and clinical/preclinical materials.
• **Chardan Capital Markets, LLC**: Entitled to a deferred underwriting commission of $2,070,000.

Stakeholder Impact

• **Shareholders**: Face significant dilution (up to 43% of outstanding shares) from new financing agreements, potential stock price decline due to discounted sales by White Lion Capital, and no anticipated cash dividends. As a controlled company, they may have fewer corporate governance protections. They are also exposed to the risk of further losses and potential legal proceedings.
• **Employees**: Benefit from the Omnibus Incentive Plan designed to attract, retain, and motivate them through equity-based awards. Personnel-related expenses increased in Q1 2025.
• **Customers**: RMC's termination of the Penumbra distribution agreement may impact product offerings in South Korea, but the company aims to replace these sales. The company's focus on innovative therapies aims to improve healthcare outcomes for patients.
• **Suppliers/Creditors**: The company's prior insolvency and current legal proceedings (Benjamin Securities lawsuit) indicate potential payment risks. However, the new financing agreements are intended to address liquidity issues and manage outstanding debts.

Next Steps

• Vaximm plans to move its flagship asset, VXM01, into planned Phase 2 clinical trials for glioblastoma and initiate a new clinical trial in the United States.
• Vaximm will continue to advance other preclinical candidates (VXM04, VXM06, VXM08, VXM10) in investigational new drug (IND)-enabling studies and submit IND applications to regulatory authorities.
• Darnatein intends to continue the development and testing of its therapeutic candidates, DRT-101 and DRT-102.
• Darnatein plans to file an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration by 2025 for Phase 1 clinical trial of DRT-101, with aims of FDA approval by 2032.
• Darnatein will seek to create cashflow via licensing deals from the preclinical and clinical developments of its pipeline assets.
• RMC intends to seek to become the sales representative of other neuro-intervention medical device equipment manufacturers to replace sales lost from the Penumbra agreement.
• RMC plans to expand sales of products offered by companies it currently represents.
• The company will use the net proceeds obtained under the Issuance Agreements to fund clinical trials of its product candidates, preclinical product candidates, potential acquisition or in-licensing activities, and working capital and general corporate purposes.
• The company expects to incur and report R&D related expenses mainly from its subsidiaries actively engaged in R&D at an estimated amount of $2.5 million to $3.0 million per quarter beginning from the middle of 2025, which could potentially increase to $5.0 million to $6.0 million per quarter.
• The company will objectively assess and choose commercialization options that maximize potential value, including internal advancement, strategic partnerships, and spin-outs or public offerings.
• The company may eventually build an in-house marketing and sales management organization.
• The company intends to manage all valid arrears in its debts and liability accounts as soon as monies become available from anticipated near-term financing arrangements.
• The first Convertible Note in the principal amount of $445,000 shall close on or before one day after the filing of this registration statement.
• The second Convertible Note in the principal amount of $665,000 shall close one day after this registration statement becomes effective.

Key Dates

Recommendation

Keywords

Healthcare, Biotechnology, Pharmaceuticals, Medical Devices, Immunotherapies, Oncology, Glioblastoma, Osteoarthritis, Neurovascular, Drug Development, Clinical Trials, Preclinical Studies, SEC Filing, S-1/A, Equity Line of Credit, Warrants, Convertible Notes, Capital Raise, Dilution, Nasdaq, Corporate Governance, Risk Management, South Korea, Switzerland, Vaximm, Darnatein, RMC, White Lion Capital